chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Feeling abnormal, SARS-CoV-2 test, Tinnitus
Clinical narrative: Have ringing in my ears, which never had before.; Dizziness; Foggy head; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 23Mar2021 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 02Mar2021 as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021, the patient experienced ringing in ears which the patient never had before, dizziness and a foggy head. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in Mar2021, the patient underwent nasal swab and the result was unknown. The clinical outcome of the events ringing in ears, dizziness and foggy head was not recovered at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 44.0
Sex: M
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: Headache; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 21Apr2021 at 09:00 (at the age of 44-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 21:00, the patient experienced headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event headache was recovered on an unknown date in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Vaccination site pain
Clinical narrative: Sore muscles; Injection site pain; This is a spontaneous report from a non-contactable consumer, the patient. A 31-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 11:00 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Medical history included allergy to nuts and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medications included ascorbic acid (VITAMIN C), zinc (MANUFACTURER UNKNOWN) and sitosterol (CHOLEST-OFF); all from unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021 the patient experienced sore muscles and injection site pain. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore muscles and injection site pain were not resolved at this time of report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Headache, Pyrexia
Clinical narrative: All over body chills; Fever; Headache; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 21Apr2021 at 16:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included magnesium (MANUFACTURER UNKNOWN), vitamin b (MANUFACTURER UNKNOWN), ascorbic acid (VITAMIN C), fish oil (MANUFACTURER UNKNOWN) and iron (MANUFACTURER UNKNOWN); all for unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 31Mar2021 at 16:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 04:00, the patient experienced all over body chills, fever and headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as the result of events. The clinical outcome of the events all over body chills, fever and headache were recovering at the time of this report.  No follow-up attempts are possible. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Lymph node pain, Nausea
Clinical narrative: Pain in underarm lymph node that started two days after second dose and persisted for 4 days; Also had nausea the night of the second dose; This is a spontaneous report from a non-contactable consumer, the patient. A patient of an unknown gender and age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 14Apr2021 at 17:00 as a single dose for COVID-19 immunisation. Medical history of the patient was not reported. The patient did not have any allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications included oral birth control (MANUFACTURER UNKNOWN) from an unknown date. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 26Mar2021 at 15:00 as a single dose for COVID-19 immunisation. On an unknown date in Apr2021, the patient experienced pain in underarm lymph node that started two days after second dose and persisted for four days. It was reported that the patient did not experience this pain during the first dose, also had nausea the night of the second dose. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain in underarm lymph node, nausea was recovered on an unspecified date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Vertigo after 20 hours of injection. two days later still have vertigo.; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8736) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. Medical history included fatty liver and primary biliary cholangitis. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included ursodeoxycholic acid (URSODIOL) for unknown indication on unknown date and unknown if ongoing. The patient had no known allergies. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: GP7533) via an unspecified route of administration in the left arm on 26Mar2021 at 10:45 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 00:00, 20 hours after vaccination, the patient experienced vertigo. Two days later still the patient had vertigo. The event did not result in doctor or other healthcare professional office/clinic visit.  No therapeutic measures were taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event vertigo was not recovered at the time of the this report.  No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Chromaturia
Clinical narrative: Urine turned neon yellow; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 21Apr2021 at 14:30 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included fluvoxamine maleate (LUVOX) for an unknown indication from an unknown date and unknow if ongoing. On 21Apr2021 at 20:30, the patient urine turned neon yellow later that night. The next day, patient's urine was still a bit yellow now, but much less than before. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of adverse event. The clinical outcome of the event urine turned neon yellow was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen armpit/lymph nodes in the arm where shot was given.; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 17Apr2021 at 11:15 (at the age of 45-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Apr2021, the patient experienced swollen armpit/ lymph nodes in the arm where shot was given. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of both the event swollen armpit/ lymph nodes in the arm where shot was given was unknown at the time of this report.    No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: Dizzy; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 (at the age of 47-years-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medication was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Apr2021, the patient felt dizzy. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dizzy was unknown at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Axillary pain, Headache, Mobility decreased, Pain in extremity
Clinical narrative: The second dose has given me terrible headaches; Pain in the left arm; Pain in the left armpit; I am unable to fully use my left arm. The mobility of it is highly restricted due to the pain in the bicep/armpit.; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8732) via an unspecified route of administration in the left arm on 20Apr2021 at 14:15 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Medical history included psoriatic arthritis, osteoarthritis, hypertension, pre-diabetes and psoriasis. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included bisoprolol (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and metformin (MANUFACTURER UNKNOWN) all for an unknown indications since an unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EN6202) via an unspecified route of administration in the left arm on 31Mar2021 at 12:15 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. On 20Apr2021 at 21:00, the second dose had given the patient terrible headaches, pain in his left arm / left armpit that was of a similar feeling to a torn muscle (specifically centered around the vaccination site) and the patient was unable to fully use his left arm. The mobility of it was highly restricted due to the pain in the bicep / armpit. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the adverse events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events terrible headaches, pain in the left arm / left armpit and mobility was highly restricted was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Balance disorder, Headache, Nausea
Clinical narrative: Huge headache and felt very weak for the entire next day; Huge headache and felt very weak for the entire next day; Nausea and massive feeling of imbalance.; Nausea and massive feeling of imbalance.; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 19Apr2021 at 18:00 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. The patient previously took amoxicillin (MANUFACTURER UNKNOWN) for unknown indication on unknown date and experienced drug allergy. Concomitant medications taken within two weeks of vaccination included escitalopram oxalate (LEXAPRO), bupropion hydrochloride (WELLBUTRIN) and Probiotics; all from unknown date for unknown indication. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 29Mar2021 at 18:00 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Apr2021 at 21:00, the patient experienced nausea and massive feeling of imbalance. The patient experienced huge headache and felt very weak for the entire next day on 20Apr2021. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events nausea and massive feeling of imbalance, huge headache and felt very weak for the entire next day was resolving at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 19.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Nausea, SARS-CoV-2 test, Vomiting
Clinical narrative: Dizziness; Nauseous; Vomiting; This is a spontaneous report from a non-contactable consumer. A 19-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 19Apr2021 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021, the patient experienced nauseous/vomiting for 4 days and dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had been tested for COVID-19. On an unknown date in Apr2021, the patient underwent nasal swab test for COVID-19 and the result was negative. Therapeutic measures were taken as a result of nauseous/vomiting and included treatment with unspecified anti-nausea medication. The clinical outcome of the events nauseous and vomiting were recovered on 23Apr2021 while dizziness was unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Decreased appetite, Headache, Hot flush, Pain in extremity
Clinical narrative: Headache; Left arm pain; Back pain; Vaginal pain; Hot flashes; Lack of appetite; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 22Apr2021 at 15:00 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. Medical history included mitral valve prolapse, allergy to nuts (tree nuts), allergy (poppy seeds) and sulfonamide allergy.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included vitamin d nos (MANUFACTURER UNKNOWN) taken for unknown indication on unknown date and unknown if ongoing. The patient previously took cefdinir (OMNICEF) and tobramycin (TOBREX); both on unknown dates for unspecified indications and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 01Apr2021 at 09:30 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. On 23Apr2021 at 05:30, the patient experienced headache, left arm pain, back pain, vaginal pain, hot flashes and lack of appetite. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with Tylenol. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, left arm pain, back pain, vaginal pain, hot flashes and lack of appetite were resolved on 23Apr2021.    No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Vulvovaginal pain
Clinical narrative: Headache; Left arm pain; Back pain; Vaginal pain; Hot flashes; Lack of appetite; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0171) via an unspecified route of administration in the left arm on 22Apr2021 at 15:00 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. Medical history included mitral valve prolapse, allergy to nuts (tree nuts), allergy (poppy seeds) and sulfonamide allergy.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included vitamin d nos (MANUFACTURER UNKNOWN) taken for unknown indication on unknown date and unknown if ongoing. The patient previously took cefdinir (OMNICEF) and tobramycin (TOBREX); both on unknown dates for unspecified indications and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 01Apr2021 at 09:30 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. On 23Apr2021 at 05:30, the patient experienced headache, left arm pain, back pain, vaginal pain, hot flashes and lack of appetite. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with Tylenol. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, left arm pain, back pain, vaginal pain, hot flashes and lack of appetite were resolved on 23Apr2021.    No follow-up attempts are possible. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Ringing in ears (previously had it maybe 1 or 2 days per month) much worse and all the time; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 09Apr2021 at 10:00 (at the age of 50-years-old) as single dose for COVID-19 immunisation. Medical history included migraine and ongoing tinnitus. Prior to vaccination, the patient was not diagnosed with COVID-19. On 13Apr2021, the patient experienced ringing in ears (previously had it for 1 or 2 days per month) much worse and all the time. Pitch of ringing went up and down throughout day. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event ringing in ears (previously had it for 1 or 2 days per month) much worse and all the time was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Vaccination site pain
Clinical narrative: Injection site soreness; Fatigue; Mild headache; This is a spontaneous report from a non-contactable pharmacist. A 37-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date in Apr2021 (at the age of 37-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within 2 weeks of the vaccination and other vaccines within four weeks prior to the COVID vaccine. On 02Apr2021, the patient experienced injection site soreness, fatigue and mild headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site soreness, fatigue and mild headache were resolving at the time of this report. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 22Apr2021 (at the age of 37-years-old), as a single dose for COVID-19 immunisation.    No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Anticoagulant therapy, Intracardiac thrombus, Subdural haematoma
Clinical narrative: This patient was hospitalized with cardiac valve thrombosis within 5 days of being administered the 3rd booster immunization. patient was then put on a heparin infusion to manage the thrombosis and then proceeded to develope a 15mm subdural hematoma.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Chills, Fatigue, Headache
Clinical narrative: Headache; Fatigue; Chills; Fever; ache moving down through neck,; Joint pain; Weakness in knees, ankles, arms; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 21Apr2021 at 11:45 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included Barrett's esophagus and food allergies (Zucchini and seafood/fish). The patient did not receive any concomitant medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19.The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 31Mar2021 at 10:45 as a single dose for COVID-19 immunisation. On 21Apr2021, the patient had sudden onset of headache and fatigue after approximately 10 hours sudden onset of chills approximately 11 hours. Fever and constant shivering and ache moving down through neck, shoulders, and lower back after approximately 12.5 hours. Joint pain and weakness in knees, ankles, arms after approximately 13 hours. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, chills, fatigue, neck pain, shoulders pain, lower back pain, joint pain and  weakness in knees, ankles, arms was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia
Clinical narrative: Headache; Fatigue; Chills; Fever; ache moving down through neck,; Joint pain; Weakness in knees, ankles, arms; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 21Apr2021 at 11:45 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included Barrett's esophagus and food allergies (Zucchini and seafood/fish). The patient did not receive any concomitant medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19.The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in the left arm on 31Mar2021 at 10:45 as a single dose for COVID-19 immunisation. On 21Apr2021, the patient had sudden onset of headache and fatigue after approximately 10 hours sudden onset of chills approximately 11 hours. Fever and constant shivering and ache moving down through neck, shoulders, and lower back after approximately 12.5 hours. Joint pain and weakness in knees, ankles, arms after approximately 13 hours. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, chills, fatigue, neck pain, shoulders pain, lower back pain, joint pain and  weakness in knees, ankles, arms was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Fatigue, Feeling abnormal, Pain in extremity, Yawning
Clinical narrative: Tiredness; Lack of energy; Foggy; excessive yawning.; Sore arm; This is a spontaneous report from a contactable healthcare professional, the patient. A 41-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 15Apr2021 at 15:00 (at the age of 41-year-old) as a single dose for COVID-19 immunization. Medical history was not reported. The patient previously took Aspirin and experienced allergy to it. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included valaciclovir (MANUFACTURER UNKNOWN) and bupropion (MANUFACTURER UNKNOWN), both for unknown indication and from an unknown date. On 15Apr2021, on the day on vaccination the patient experienced sore arm. On 21Apr2021, the patient had tiredness/lack of energy, foggy, and excessive yawning. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events sore arm, tiredness/lack of energy, foggy, and excessive yawning was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Burning sensation, Chills, Fatigue, Glossodynia
Clinical narrative: injection site pain; tiredness; headache; muscle pain; chills; fever; joint pain; throat hurts; tongue sensitive (burn sensation); tongue sensitive (burn sensation); start spotting brown blood; This is a spontaneous report from a contactable consumer (patient). A 44-years-old non pregnant female patient received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 20Apr2021 12:00 (at the age of 44-years old) (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation. The patient was not pregnant at the time of vaccination. The patient had no medical history. The patient had no known allergies. The patient's concomitant medications were not reported. The patient had no other vaccine in four weeks, no covid prior vaccination and no covid tested post vaccination. The patient experienced injection site pain, tiredness, headache, muscle pain, chills, fever, joint paint, throat hurts, tongue sensitive (burn sensation), start spotting brown blood on 20Apr2021 13:00. The latency between suspect and event was of 1 hour. The patient received no treatments in response to events. The clinical outcome of events was unknown.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts are completed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Oropharyngeal pain, Pyrexia, Vaccination site pain
Clinical narrative: injection site pain; tiredness; headache; muscle pain; chills; fever; joint pain; throat hurts; tongue sensitive (burn sensation); tongue sensitive (burn sensation); start spotting brown blood; This is a spontaneous report from a contactable consumer (patient). A 44-years-old non pregnant female patient received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 20Apr2021 12:00 (at the age of 44-years old) (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation. The patient was not pregnant at the time of vaccination. The patient had no medical history. The patient had no known allergies. The patient's concomitant medications were not reported. The patient had no other vaccine in four weeks, no covid prior vaccination and no covid tested post vaccination. The patient experienced injection site pain, tiredness, headache, muscle pain, chills, fever, joint paint, throat hurts, tongue sensitive (burn sensation), start spotting brown blood on 20Apr2021 13:00. The latency between suspect and event was of 1 hour. The patient received no treatments in response to events. The clinical outcome of events was unknown.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts are completed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Vaginal haemorrhage
Clinical narrative: injection site pain; tiredness; headache; muscle pain; chills; fever; joint pain; throat hurts; tongue sensitive (burn sensation); tongue sensitive (burn sensation); start spotting brown blood; This is a spontaneous report from a contactable consumer (patient). A 44-years-old non pregnant female patient received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, Solution for injection), dose 1 via an unspecified route of administration, administered in Arm Left on 20Apr2021 12:00 (at the age of 44-years old) (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation. The patient was not pregnant at the time of vaccination. The patient had no medical history. The patient had no known allergies. The patient's concomitant medications were not reported. The patient had no other vaccine in four weeks, no covid prior vaccination and no covid tested post vaccination. The patient experienced injection site pain, tiredness, headache, muscle pain, chills, fever, joint paint, throat hurts, tongue sensitive (burn sensation), start spotting brown blood on 20Apr2021 13:00. The latency between suspect and event was of 1 hour. The patient received no treatments in response to events. The clinical outcome of events was unknown.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts are completed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Blepharospasm
Clinical narrative: Eyes were twitching and kept switching from right to left; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 30Mar2021 at 12:00 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 31Mar2021, the patient experienced eyes were twitching and kept switching from right to left for 2 days after the first vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event eyes was twitching and kept switching from right to left was recovered on 02Apr2021.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Pain in extremity
Clinical narrative: Sore arm; Slight chills; Low energy; This is a spontaneous report from a contactable consumer, the patient. A 62-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the right arm on 22Apr2021 at 19:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as thyroid cancer survivor. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included levothyroxine sodium (SYNTHROID 88), cetirizine hydrochloride (ZYRTEC), paracetamol (TYLENOL ES), multivitamin (MANUFACTURER UNKNOWN) and vi (MANUFACTURER UNKNOWN), all for unknown indications from unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the right arm on 01Apr2021 at 19:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 09:30, the patient experienced sore arm, slight chills and low energy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events sore arm, slight chills and low energy was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Migraine, Photophobia
Clinical narrative: migraine headache; light sensitivity; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on an unknown date in Mar2021 at 12:15 (at the age of 57-year-old) and a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 15Apr2021 at 11:45 (at the age of 57-year-old) as a dose for COVID-19 immunisation. Medical history included penicillin allergy, migraine. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications were not reported. On an unknown date in Mar2021, the patient experienced a migraine headache with light sensitivity (About 3 days post both vaccines). The migraine and light sensitivity was worse after the second shot. Patient stated that she had migraines before, but would not say that she was a habitual migraine sufferer. In the past, they had only been brought on by stress or loud perfumes. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events migraine headache with light sensitivity, the migraine and light sensitivity was worse after the second shot was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Dry mouth
Clinical narrative: Dry mouth; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 22Apr2021 at 10:00 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient had known allergies to dust mite and pollen. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included montelukast (MANUFACTURER UNKNOWN) and budesonide/ formoterol fumarate (SYMBICORT); both from unknown dates for unknown indications and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 13:00, the patient experienced dry mouth. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event dry mouth was unknown at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dyskinesia, Gait inability, Tremor
Clinical narrative: Within four hours of receiving the vaccine body started shaking slightly; Another couple hours go by and entire body was jerking,; Could not even walk; Teeth were chattering; This is a spontaneous report from a contactable consumer, the patient. A 17-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the right arm on 21Apr2021 at 18:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. Medical history included acid reflux when the patient was younger kid. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the right arm on 31Mar2021 at 18:00 (at the age of 17-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On 21Apr2021 at 22:00, within four hours of receiving the vaccine, the patient experienced body shaking slightly, another couple hours go by and the entire body was jerking and her teeth were chattering (all uncontrollably). The patient could not even walk due to how intensely the jerking/shaking was. This continued all through the night, and didn't stop until around 8:00 the following morning. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of events body started shaking slightly, the entire body was jerking, could not even walk and teeth were chattering were unknown at this time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Anxiety, Aphasia, Chills, Feeling abnormal, Myalgia
Clinical narrative: Speechless; Brain fog; Anxiety attack; Feel awful.; Fever; Muscle ache; Chills; Tingling in head and lowered back; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old, non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0162) via an unspecified route of administration on 09Apr2021 at 13:45 (at an age of 40-years-old) as single dose for COVID-19 immunisation. The patient did not have any medical history. The patient had no allergies to medications, food, or other products. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within 4 weeks prior to COVID vaccine. The patient did not receive any concomitant medications.  On 16Apr2021, the patient had tingling in head and lowered back, chills, fever, speechless, brain fog, anxiety attack, muscle ache symptoms were on going for a week, felt awful. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events of tingling in head and lowered back, chills, fever, speechless, brain fog, anxiety attack, muscle ache and felt awful were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.